Guardant Health (GH) Reports Q3 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +18.75% and +13.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17h ago
More News
New Strong Sell Stocks for Oct. 17th
GYRE, DAR and CRLBF have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2025.
Zacks·13d ago
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength?
Septerna, Inc. (SEPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·21d ago
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of +8.74% and -54.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) delivered earnings and revenue surprises of -67.57% and -79.20%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
Gyre Therapeutics (GYRE) has shared an announcement. Gyre Therapeutics, Inc. has reported a vacancy on its Audit Committee following the resignatio...
TipRanks Financial Blog·1y ago
Gyre Therapeutics (GYRE, $15.85) price exceeded its 50-day Moving Average on April 01, 2024
This price move could indicate a change in the trend, and may be a sell signal for investors...
Tickeron - Stocks·2y ago
Gyre Therapeutics Inc (GYRE) Announces Full Year 2023 Financial Outcomes and Business Progress
Transformational Year with Strategic Shifts and Clinical AdvancesRelated Stocks: GYRE...
GuruFocus·2y ago
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Data readout from Phase 3 clinical trial in the People's Republic of China ( PRC ) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical...